Commissioner Gottlieb has shown strong leadership in both his words and actions to increase access to biosimilars and bring real savings to the U.S. healthcare system. He has been a true advocate for patients and meaningful solutions with the FDA’s Biosimilars Action Plan, pointing to the fact that Americans could have saved more than $4.5B with access to approved biosimilars in 2017 alone.
The Forum has appreciated his commitment to support and the need for increase uptake of biosimilars in the U.S. market, putting us on a path to realize the full cost saving benefits these treatments can offer. But it’s clear more work needs to be done. As Congress debates solutions to rising health care costs, it’s been voices like Commissioner Gottlieb’s that are needed to properly highlight the safety, effectiveness and lower costs of these treatments and combat the rampant misinformation that is hurting the U.S. biosimilars market.
SOURCE: Biosimilars Forum